adenine has been researched along with Multiple Myeloma in 31 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies." | 9.34 | A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A, 2020) |
| "This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)." | 9.27 | Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018) |
| "Resveratrol, a natural compound extracted from the skins of grapes, berries, or other fruits, has been shown to have anti-tumor effects against multiple myeloma (MM) via promoting apoptosis and inhibiting cell viability." | 8.02 | Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells. ( Cheng, T; Lai, W; Lu, Y; Ma, R; Peng, Y; Shi, B; Shi, J; Wang, Y; Wu, X; Yang, G; Yi, H; Yu, D, 2021) |
| "Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed." | 6.94 | Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anderson, LD; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Girnius, S; Karanes, C; Lee, Y; Liu, E; Lunning, M; Matous, JV; Niesvizky, R; Salman, Z; Shustik, C; Stuart, R; Usmani, SZ; Valent, J, 2020) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 5.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| "We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies." | 5.34 | A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anagnostopoulos, A; Briso, EM; Cascavilla, N; Dobkowska, E; García Sanz, R; Hajek, R; Hauns, B; Lee, Y; Martin Sánchez, J; Oriol, A; Ozcan, M; Pour, L; Špička, I; Terjung, A, 2020) |
| "This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent)." | 5.27 | Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. ( Anderson, LD; Bilotti, E; Chang, L; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Graef, T; Holkova, B; Karanes, C; Larson, S; Lee, Y; Lunning, M; Matous, JV; Niesvizky, R; Pak, Y; Salman, Z; Usmani, SZ; Valent, J, 2018) |
| "Resveratrol, a natural compound extracted from the skins of grapes, berries, or other fruits, has been shown to have anti-tumor effects against multiple myeloma (MM) via promoting apoptosis and inhibiting cell viability." | 4.02 | Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells. ( Cheng, T; Lai, W; Lu, Y; Ma, R; Peng, Y; Shi, B; Shi, J; Wang, Y; Wu, X; Yang, G; Yi, H; Yu, D, 2021) |
| " In this study we report for the first time that ibrutinib is cytotoxic to malignant plasma cells from patients with multiple myeloma (MM) and furthermore that treatment with ibrutinib significantly augments the cytotoxic activity of bortezomib and lenalidomide chemotherapies." | 3.79 | BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. ( Barrera, LN; Bowles, KM; MacEwan, DJ; Murray, MY; Rushworth, SA; Zaitseva, L, 2013) |
| "The proteasome inhibitor Bortezomib has been approved for the treatment of relapsed/refractory multiple myeloma (MM), thanks to its ability to induce MM cell apoptosis." | 3.76 | Bortezomib induces autophagic death in proliferating human endothelial cells. ( Belloni, D; Caligaris-Cappio, F; Dell'Antonio, G; Ferrarini, M; Ferrero, E; Foglieni, C; Veschini, L, 2010) |
| "Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed." | 2.94 | Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. ( Anderson, LD; Chari, A; Chhabra, S; Cornell, RF; Gasparetto, C; Girnius, S; Karanes, C; Lee, Y; Liu, E; Lunning, M; Matous, JV; Niesvizky, R; Salman, Z; Shustik, C; Stuart, R; Usmani, SZ; Valent, J, 2020) |
| "Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV." | 1.48 | Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018) |
| " We here compare bortezomib with carfilzomib and LU-102 in MM and MCL in vitro with regard to their effects on pIκB/NF-κB signaling and their cytotoxic activity in combination with ibrutinib." | 1.42 | The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. ( Bader, J; Besse, L; de Bruin, G; Driessen, C; Geurink, PP; Kisselev, AF; Kraus, J; Kraus, M; Liu, N; Overkleeft, H, 2015) |
| "We show here that treatment of human multiple myeloma (MM) cells with 17DMAG induces mTOR inhibition and microtubule-associated protein light chain 3 (LC3) conversion (LC3-I to LC3-II), an indicator of autophagy." | 1.36 | Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis. ( López-Pérez, AI; López-Rivas, A; Martín-Pérez, R; Palacios, C; Pandiella, A, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 1 (3.23) | 29.6817 |
| 2010's | 22 (70.97) | 24.3611 |
| 2020's | 6 (19.35) | 2.80 |
| Authors | Studies |
|---|---|
| Santoni, G | 1 |
| Amantini, C | 1 |
| Maggi, F | 1 |
| Marinelli, O | 1 |
| Santoni, M | 1 |
| Morelli, MB | 1 |
| Hajek, R | 1 |
| Pour, L | 1 |
| Ozcan, M | 1 |
| Martin Sánchez, J | 1 |
| García Sanz, R | 1 |
| Anagnostopoulos, A | 1 |
| Oriol, A | 1 |
| Cascavilla, N | 1 |
| Terjung, A | 1 |
| Lee, Y | 3 |
| Briso, EM | 1 |
| Dobkowska, E | 1 |
| Hauns, B | 1 |
| Špička, I | 1 |
| Li, A | 1 |
| Li, X | 1 |
| Chen, X | 2 |
| Zeng, C | 1 |
| Wang, Z | 1 |
| Li, Z | 1 |
| Chen, J | 1 |
| Chari, A | 2 |
| Cornell, RF | 2 |
| Gasparetto, C | 2 |
| Karanes, C | 2 |
| Matous, JV | 2 |
| Niesvizky, R | 2 |
| Lunning, M | 2 |
| Usmani, SZ | 2 |
| Anderson, LD | 3 |
| Chhabra, S | 2 |
| Girnius, S | 1 |
| Shustik, C | 1 |
| Stuart, R | 1 |
| Salman, Z | 3 |
| Liu, E | 1 |
| Valent, J | 2 |
| Dou, R | 1 |
| Qian, J | 1 |
| Wu, W | 1 |
| Zhang, Y | 2 |
| Yuan, Y | 1 |
| Guo, M | 2 |
| Wei, R | 1 |
| Yang, S | 1 |
| Jurczyszyn, A | 1 |
| Janz, S | 2 |
| Beksac, M | 1 |
| Gu, C | 1 |
| Yang, Y | 3 |
| Ma, R | 1 |
| Yu, D | 1 |
| Peng, Y | 1 |
| Yi, H | 1 |
| Wang, Y | 3 |
| Cheng, T | 1 |
| Shi, B | 1 |
| Yang, G | 2 |
| Lai, W | 1 |
| Wu, X | 1 |
| Lu, Y | 1 |
| Shi, J | 2 |
| Ma, J | 1 |
| Gong, W | 1 |
| Liu, S | 1 |
| Li, Q | 2 |
| Wang, J | 1 |
| Wang, S | 1 |
| Chen, N | 1 |
| Liu, Q | 1 |
| Zhao, H | 1 |
| Richardson, PG | 1 |
| Bensinger, WI | 1 |
| Huff, CA | 1 |
| Costello, CL | 1 |
| Lendvai, N | 1 |
| Berdeja, JG | 1 |
| Siegel, DS | 1 |
| Lebovic, D | 1 |
| Jagannath, S | 1 |
| Laubach, JP | 1 |
| Stockerl-Goldstein, KE | 1 |
| Kwei, L | 1 |
| Clow, F | 1 |
| Elias, L | 2 |
| Graef, T | 2 |
| Bilotti, E | 2 |
| Vij, R | 1 |
| Larson, S | 1 |
| Holkova, B | 1 |
| Chang, L | 1 |
| Pak, Y | 1 |
| Gertz, MA | 1 |
| Ito, T | 1 |
| Ando, T | 1 |
| Suzuki-Karasaki, M | 1 |
| Tokunaga, T | 1 |
| Yoshida, Y | 1 |
| Ochiai, T | 1 |
| Tokuhashi, Y | 1 |
| Suzuki-Karasaki, Y | 1 |
| Alsunaid, SR | 1 |
| Ashraf, H | 1 |
| Soubani, AO | 1 |
| Cameron, F | 1 |
| Sanford, M | 1 |
| Zhang, Q | 1 |
| Xia, B | 1 |
| Qu, F | 1 |
| Yuan, T | 1 |
| Guo, S | 1 |
| Zhao, W | 1 |
| Yang, H | 1 |
| Murray, MY | 2 |
| Zaitseva, L | 2 |
| Auger, MJ | 1 |
| Craig, JI | 1 |
| MacEwan, DJ | 2 |
| Rushworth, SA | 2 |
| Bowles, KM | 2 |
| Gu, Z | 1 |
| Salama, ME | 1 |
| Das, S | 1 |
| Wendlandt, E | 1 |
| Xu, H | 1 |
| Huang, J | 1 |
| Tao, Y | 1 |
| Hao, M | 1 |
| Franqui, R | 1 |
| Levasseur, D | 1 |
| Tricot, G | 1 |
| Zhan, F | 1 |
| Kraus, J | 1 |
| Kraus, M | 1 |
| Liu, N | 1 |
| Besse, L | 1 |
| Bader, J | 1 |
| Geurink, PP | 1 |
| de Bruin, G | 1 |
| Kisselev, AF | 1 |
| Overkleeft, H | 1 |
| Driessen, C | 1 |
| Berglöf, A | 1 |
| Hamasy, A | 1 |
| Meinke, S | 1 |
| Palma, M | 1 |
| Krstic, A | 1 |
| Månsson, R | 1 |
| Kimby, E | 1 |
| Österborg, A | 1 |
| Smith, CI | 1 |
| Smith, LL | 1 |
| Hoang, B | 1 |
| Benavides, A | 1 |
| Shi, Y | 1 |
| Frost, P | 1 |
| Lichtenstein, A | 1 |
| Belloni, D | 1 |
| Veschini, L | 1 |
| Foglieni, C | 1 |
| Dell'Antonio, G | 1 |
| Caligaris-Cappio, F | 1 |
| Ferrarini, M | 1 |
| Ferrero, E | 1 |
| Palacios, C | 1 |
| Martín-Pérez, R | 1 |
| López-Pérez, AI | 1 |
| Pandiella, A | 1 |
| López-Rivas, A | 1 |
| Pan, Y | 1 |
| Gao, Y | 1 |
| Chen, L | 2 |
| Gao, G | 1 |
| Dong, H | 1 |
| Dong, B | 1 |
| Tai, YT | 2 |
| Chang, BY | 1 |
| Kong, SY | 1 |
| Fulciniti, M | 1 |
| Calle, Y | 1 |
| Hu, Y | 1 |
| Lin, J | 1 |
| Zhao, JJ | 1 |
| Cagnetta, A | 1 |
| Cea, M | 1 |
| Sellitto, MA | 1 |
| Zhong, MY | 1 |
| Wang, Q | 1 |
| Acharya, C | 1 |
| Carrasco, DR | 1 |
| Buggy, JJ | 1 |
| Treon, SP | 1 |
| Matsui, W | 1 |
| Richardson, P | 1 |
| Munshi, NC | 1 |
| Anderson, KC | 2 |
| Zhao, S | 1 |
| Ma, CM | 1 |
| Liu, CX | 1 |
| Wei, W | 1 |
| Sun, Y | 1 |
| Yan, H | 1 |
| Wu, YL | 1 |
| Edwards, CM | 1 |
| Barrera, LN | 1 |
| Gao, LS | 1 |
| Zhang, XH | 1 |
| Zhang, H | 1 |
| Zhang, YY | 1 |
| Fu, JX | 1 |
| Hanson, KH | 1 |
| Crowley, J | 1 |
| Salmon, SE | 1 |
| Keppen, M | 1 |
| Braun, TJ | 1 |
| Bonnet, JD | 1 |
| Volkman, LE | 1 |
| Krueger, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial[NCT05020392] | Phase 3 | 24 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for adenine and Multiple Myeloma
| Article | Year |
|---|---|
Ibrutinib: first global approval.
Topics: Adenine; Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular | 2014 |
Targets for Ibrutinib Beyond B Cell Malignancies.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Atrial Fibrillation; Humans; Leukemia, Lympho | 2015 |
5 trials available for adenine and Multiple Myeloma
| Article | Year |
|---|---|
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; | 2020 |
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2020 |
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dis | 2018 |
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2018 |
Evaluation of amonafide in refractory and relapsing multiple myeloma: a Southwest Oncology Group study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Drug Resistance; Female; Granulocytes | 1991 |
24 other studies available for adenine and Multiple Myeloma
| Article | Year |
|---|---|
The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment.
Topics: Adenine; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Pipe | 2022 |
NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mTOR Pathway.
Topics: Adenine; Apoptosis; Autophagy; Basic Helix-Loop-Helix Transcription Factors; Bone Marrow Cells; Cell | 2020 |
Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenine; Animals; Antineoplasti | 2021 |
Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells.
Topics: Adenine; Adenosine Monophosphate; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; A | 2021 |
Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-κB and STAT3.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Cell Line, Tumor; Cell Proliferation; Female; Ge | 2018 |
Multiple myeloma - a cure within reach.
Topics: Adenine; Humans; Multiple Myeloma; Oligopeptides; Piperidines; Pyrazoles; Pyrimidines | 2018 |
Cold PSM, but not TRAIL, triggers autophagic cell death: A therapeutic advantage of PSM over TRAIL.
Topics: A549 Cells; Adenine; Autophagosomes; Autophagy; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation | 2018 |
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T | 2018 |
[Effect of PI3Kδ inhibitor CAL-101 on myeloma cell lines and preliminary study of synergistic effects with other new drugs].
Topics: Adenine; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; M | 2014 |
Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Bortezomib; Cell Survival; Drug Resistance, Neoplasm; | 2015 |
Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; beta Catenin; Bone Mar | 2015 |
The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neopla | 2015 |
58th American Society of Hematology Annual Meeting.
Topics: ADAMTS13 Protein; Adenine; Antibodies, Monoclonal; Antineoplastic Agents; Central Venous Catheters; | 2017 |
Effect of autophagy on multiple myeloma cell viability.
Topics: Adenine; Antifungal Agents; Antimalarials; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Pr | 2009 |
Bortezomib induces autophagic death in proliferating human endothelial cells.
Topics: Adenine; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Autophagy; Boronic Acids; Bortezom | 2010 |
Autophagy inhibition sensitizes multiple myeloma cells to 17-dimethylaminoethylamino-17-demethoxygeldanamycin-induced apoptosis.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Benzoquinones; HSP90 Heat-Shock Proteins; Huma | 2010 |
Targeting autophagy augments in vitro and in vivo antimyeloma activity of DNA-damaging chemotherapy.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; DNA D | 2011 |
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Bone Marrow; Cell Line, Tumor; Cell Prolifera | 2012 |
Autophagy inhibition enhances isobavachalcone-induced cell death in multiple myeloma cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cells | 2012 |
BTK inhibition in myeloma: targeting the seed and the soil.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Bone Marrow; Humans; Multiple Myeloma; Piperi | 2012 |
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Amides; Antineoplastic Agents; Boronic Acids; Bortezom | 2013 |
Bruton's tyrosine kinase: oncotarget in myeloma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Cell Growth Processes; Disease Models, Animal | 2012 |
[The influence of induced autophagy in vitro on proliferation of multiple myeloma cells].
Topics: Adenine; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Multipl | 2012 |
Characterization of C-type particles produced by a tissue culture-adapted murine myeloma.
Topics: Adenine; Animals; Cells, Cultured; Centrifugation, Density Gradient; Ethyl Ethers; Gammaretrovirus; | 1973 |